FOLH1 and metastatic neoplasm: PERTINENT FINDINGS: In this prospective, multicenter, IAEA-supported trial including 775 patients across 11 countries with varied income levels, 68Ga-PSMA-11 PET/CT identified previously undetected metastatic disease in 20.4% and prevented radical prostatectomy in 24.0%.